| Factor Information | |
|---|---|
| Data ID | 955 |
| Factor | Serum antigliadin IgM (IU/ml) |
| Description | The patients' group demonstrated a statistically highly significant increase in serum levels of IgA, IgM, and IgG class antibodies to gliadin on healthy controls (P <0.000). |
| Biomarker | NA |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | This study was designed to evaluate age-dependent serum levels of antigliadin antibodies among malnourished Egyptian infants with CHD and gastrointestinal symptoms. |
| Conclusion | The patients' group demonstrated a statistically highly significant increase in serum levels of IgA, IgM, and IgG class antibodies to gliadin on healthy controls (P < 0.000). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 494 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | TOF/TGA/PA, VSD/DORV, MGV/ASD |
| Reference | |
|---|---|
| PMID | 28293318 |
| Year | 2017 |
| Title | Gluten Sensitivity among Egyptian Infants with Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | infants | |
| Source | case-control study | |
| Region | Giza, Egypt | |
| Method | This case-control study conducted on 60 infants with established congenital heart disease. Serum antigliadin antibodies levels were measured using ELISA. | |
| Race | Africa | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Cyanotic subgpI;Acyanotic subgpII(Treatment) | Control Group(Control) |
| Number | 30； 30 | 30 |
| Age | 4-12 months (mean 8.72 ± 6.68 months) | N/A |
| Gender (Male: Female) | 36:24 (total) | N/A |
| Marker Level | 3.9±2.63;2.8±1.52 | 1.1± 0.33 |
